Literature DB >> 19404066

Outcomes and prognostic factors for squamous-cell carcinoma of the anal canal: analysis of patients from the National Cancer Data Base.

Karl Y Bilimoria1, David J Bentrem, Colin E Rock, Andrew K Stewart, Clifford Y Ko, Amy Halverson.   

Abstract

PURPOSE: The objective of this study was to assess survival and prognostic factors for anal carcinoma in the population.
METHODS: Patients with squamous-cell carcinoma of the anal canal were identified from the National Cancer Data Base (1985-2000). Univariate and multivariable methods were used to assess factors associated with survival. Concordance was calculated to assess agreement between American Joint Committee on Cancer stage and actual outcome.
RESULTS: Nineteen thousand one hundred ninety-nine patients with anal carcinoma were identified (Stage I, 25.3 percent; Stage II, 51.8 percent; Stage III, 17.1 percent; Stage IV, 5.7 percent). Overall five-year survival was 58.0 percent. The American Joint Committee on Cancer (6th edition) staging system provided good survival discrimination by stage: I, 69.5 percent; II, 59.0 percent; III, 40.6 percent; and IV, 18.7 percent (concordance index, 0.663). On multivariable analysis, patients with anal carcinoma had a higher risk of death if they were male, >or=65 years old, black, living in lower median incomes areas, and had more advanced T stage tumors, nodal or distant metastases, or poorly differentiated cancers (P < 0.0001). There was not a significant difference in survival by hospital type or year of diagnosis.
CONCLUSION: Although tumor characteristics and staging affect prognosis, patient factors, such as gender, race, and socioeconomic status, are also important prognostic factors for squamous-cell carcinoma of the anal canal.

Entities:  

Mesh:

Year:  2009        PMID: 19404066     DOI: 10.1007/DCR.0b013e31819eb7f0

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  39 in total

1.  Comparison of anal cancer outcomes in public and private hospital patients treated at a single radiation oncology center.

Authors:  Danielle S Bitterman; David Grew; Ping Gu; Richard F Cohen; Nicholas J Sanfilippo; Cynthia G Leichman; Lawrence P Leichman; Harvey G Moore; Heather T Gold; Kevin L Du
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 2.  Radiotherapy alone versus chemoradiotherapy for stage I anal squamous cell carcinoma: a systematic review and meta-analysis.

Authors:  Gaurav Talwar; Ryan Daniel; Tyler McKechnie; Oren Levine; Cagla Eskicioglu
Journal:  Int J Colorectal Dis       Date:  2021-01-24       Impact factor: 2.571

3.  Disparities in receipt of radiotherapy and survival by age, sex, and race among patients with non-metastatic squamous cell carcinoma of the anus.

Authors:  Doug M Baughman; Binay K Shah
Journal:  J Gastrointest Oncol       Date:  2016-12

Review 4.  Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations.

Authors:  Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath
Journal:  CA Cancer J Clin       Date:  2015-07-17       Impact factor: 508.702

5.  Epidermoid cancer of the anal canal.

Authors:  Shawn P Webb; Chong S Lee
Journal:  Clin Colon Rectal Surg       Date:  2011-09

6.  Successful hepatectomy for metastatic squamous cell carcinoma of the anal canal-a case report.

Authors:  Tercia Tarciane Sousa; Bruna do Nascimento Santos; Marcos Belotto; Renata D'Alpino Peixoto
Journal:  J Gastrointest Oncol       Date:  2016-12

7.  Anal canal squamous cell cancer: are surgical alternatives to chemoradiation just as effective?

Authors:  Kunal Suradkar; Emmanouil E Pappou; Steven A Lee-Kong; Daniel L Feingold; Ravi P Kiran
Journal:  Int J Colorectal Dis       Date:  2017-12-21       Impact factor: 2.571

8.  Abdominoperineal resection and perineal wound healing in recurrent, persistent, or primary anal carcinoma.

Authors:  J Hardt; S Mai; C Weiß; Peter Kienle; J Magdeburg
Journal:  Int J Colorectal Dis       Date:  2016-03-31       Impact factor: 2.571

9.  Toxicity and survival of anal cancer patients treated with intensity-modulated radiation therapy.

Authors:  A Ghareeb; K Paramasevon; P Mokool; H van der Voet; M Jha
Journal:  Ann R Coll Surg Engl       Date:  2018-11-28       Impact factor: 1.891

10.  A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer.

Authors:  Renata D'Alpino Peixoto; Dante D Wan; Devin Schellenberg; Howard J Lim
Journal:  J Gastrointest Oncol       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.